Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from BioCryst Pharmaceuticals’s reported figures.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's EBIT?
- BioCryst Pharmaceuticals (BCRX) reported EBIT of $98.47M in Q2 2026.
- How has BioCryst Pharmaceuticals's EBIT changed year-over-year?
- BioCryst Pharmaceuticals's EBIT increased by 230.6% year-over-year, from $29.79M to $98.47M.
- What is the long-term trend for BioCryst Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's EBIT has grown at a 17.7% compound annual growth rate (CAGR), from -$177.72M to $340.99M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about BioCryst Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude